Get the Stockscreener App
47.50
26.97%
8.12
Jyong Biotech Ltd stock is traded at $47.50, with a volume of 311.58K.
It is up +26.97% in the last 24 hours and down -8.78% over the past month.
Jyong Biotech Ltd is a science-driven biotechnology company based in Taiwan and is committed to developing and commercializing innovative and differentiated new drugs (plant-derived) mainly specializing in the treatment of urinary system diseases, with an initial focus on the markets of the U.S., the EU and Asia (primarily Taiwan and mainland China). It has been dedicated to the research and development of new drugs with high safety and efficacy. It has been developing a series of drug candidates, including one core drug candidate at NDA stage, one clinical-stage key drug candidate and other preclinical-stage drug candidates.
See More
Previous Close:
$39.38
Open:
$39.71
24h Volume:
311.58K
Relative Volume:
1.89
Market Cap:
$3.60B
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
-11.50%
1M Performance:
-8.78%
6M Performance:
+0.00%
1Y Performance:
+0.00%
1-Day Range:
$37.50
$52.21
1-Week Range:
$37.50
$60.58
52-Week Range:
$9.95
$67.00
Jyong Biotech Ltd Stock (MENS) Company Profile
Compare MENS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MENS
Jyong Biotech Ltd
|
47.39 | 2.99B | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
405.40 | 100.41B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
605.80 | 59.59B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
463.61 | 59.77B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
774.96 | 45.14B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
345.21 | 37.42B | 3.81B | -644.79M | -669.77M | -6.24 |
Jyong Biotech Ltd Stock (MENS) Latest News
Jyong Biotech (NASDAQ:MENS) Shares Down 8%What's Next? - MarketBeat
Jyong Biotech (NASDAQ:MENS) Shares Gap DownTime to Sell? - MarketBeat
Jyong Biotech Wins Innovation Gold Award in Pharmaceutical Category at 2025 Taipei Biotech Awards - GlobeNewswire
First Taiwan-Developed Botanical Drug in FDA Phase III: Jyong Biotech Wins Gold for BPH Treatment - Stock Titan
Jyong Biotech (NASDAQ:MENS) Trading Down 6.1%Here's Why - MarketBeat
MENS Stock Price and Chart — NASDAQ:MENS - TradingView
Jyong Biotech (NASDAQ:MENS) Reaches New 52-Week HighStill a Buy? - MarketBeat
Jyong Biotech (NASDAQ:MENS) Shares Gap UpHere's Why - MarketBeat
Jyong Biotech Chairwoman and CEO Set to Attend as Speaker at 2025 Global Business Forum in Taipei - GlobeNewswire
Taiwan Biotech Leader Joins Global Business Forum: Jyong CEO to Discuss Cross-Border Innovation - Stock Titan
Jyong Biotech (NASDAQ:MENS) Stock Price Down 4.7%Should You Sell? - MarketBeat
Jyong Biotech completes patient enrollment in Phase II trial of MCS-8 - TipRanks
Jyong Biotech Announces Completion of Patient Enrollment of - GlobeNewswire
Jyong Biotech (NASDAQ:MENS) Sets New 12-Month HighHere's Why - MarketBeat
Enrollment goal met in trial of MCS-8 for prostate cancer prevention - Urology Times
Jyong Biotech completes phase II enrollment of 700+ patients for MCS-8 in prostate cancer prevention trial - MarketScreener
Jyong Biotech (MENS) Wraps Up Phase II Enrollment for Cancer Drug Study - GuruFocus
Jyong Biotech Completes Enrollment in Phase 2 Trial of Prostate Cancer Investigational Drug - MarketScreener
700+ Patient Milestone: Jyong Biotech's Prostate Cancer Prevention Drug Advances in Phase II Trial - Stock Titan
Jyong Biotech (NASDAQ:MENS) Trading Up 9.1%What's Next? - MarketBeat
Evaluating Jyong Biotech (NasdaqGM:MENS): What Recent Price Moves Reveal About Its Current Valuation - Yahoo Finance
Examining Jyong Biotech (NasdaqGM:MENS) Valuation Following Recent Share Price Momentum - simplywall.st
Shared decision-making: Clarifying roles in prostate cancer care - Urology Times
Biopharma IPO activity slows, but 2025 returns are surging - BioWorld MedTech
Jyong Biotech (NASDAQ:MENS) Sets New 52-Week HighStill a Buy? - MarketBeat
These Were the 5 Top-Performing Stocks in the Nasdaq Composite in August 2025 - The Motley Fool
Jyong Biotech shares rise 1.06% premarket after being included in a stock market index. - AInvest
Experts discuss the transformative potential of AI for BPH - Urology Times
Jennifer Robles, MD, on future advancements in HoLEP - Urology Times
Jyong Biotech to present clinical data from studies of BOTRESO, MCS-8 - MSN
Jyong Biotech (NASDAQ:MENS) Stock Price Down 6.7%What's Next? - MarketBeat
Jyong Biotech shares rise 1.83% after-hours after participating in the 22nd Urological Association of Asia Congress. - AInvest
Jyong Biotech shares fall 1.93% after-hours following participation in the 22nd Urological Association of Asia Congress. - AInvest
Jyong Biotech Ltd. Participated in the 22nd Urological - GlobeNewswire
Breakthrough: Taiwan's First FDA Phase 3 Botanical Drug BOTRESO Shows Promise in $9.8B BPH Market - Stock Titan
Positive data on BOTRESO and MCS-8 highlight dual advances in prostate health - Urology Times
Jyong Biotech (NASDAQ:MENS) Shares Up 10.5%Here's What Happened - MarketBeat
Biopharma IPO drought continues: chance of rain expected? - BioWorld MedTech
Jennifer Robles, MD, on the impact of regional disparities in HoLEP access - Urology Times
Jyong Biotech Ltd Stock (MENS) Financials Data
There is no financial data for Jyong Biotech Ltd (MENS). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
2.06%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):